UNSPSC 51182429: Strontium ranelate

This classification denotes a bone resorption inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04NQ160FRU. European Medicines Agency schedules Strontium ranelate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20045. Strontium ranelate generally arises in the molecular formula C12H6N2O8S.2SR. The term 'strontium ranelate' is a European Medicines Agency European Public Assessment Report System designation. As of Q4 2014, STRONTIUM RANELATE remains the US FDA Preferred Term for this commodity.

Strontium ranelate bears US NLM identifiers UMLS ID C0936139 and NCI Concept Code C93265. SMILES: [Sr].[Sr].s1c(N(CC(=O)O)CC(=O)O)c(c(c1C(=O)O)CC(=O)O)C#N.

UNSPSC 51182429 Strontium ranelate, a Commodity code, reflects state and local procurement of generic and branded pharmaceutical products through cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers the primary recent opportunity in this space, procuring generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities. State and local governments buying under this code source medications through established pharmaceutical wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC — and require manufacturers to supply products with certified compliance to current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Vendors must maintain comprehensive insurance, including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, and agree to pricing structures such as fixed price, net price formats, or WAC-minus models. Issuing bodies under this code include state departments of administration and their procurement offices operating multistate cooperative agreements that span participating states and local government health facilities.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (Solicitation Number S1070000015802) on January 20, 2026, with proposals due March 26, 2026, seeking manufacturers to establish multiple contracts effective July 1, 2026, through June 30, 2028. The procurement requires vendors to supply identified pharmaceutical products with detailed National Drug Codes (NDC), SKUs, UPCs, and packaging configurations, with all products available in the marketplace by May 15, 2026. Evaluation weights cost heavily at 75 percent for price competitiveness, 10 percent for fixed pricing, and 5 percent each for administrative fee format compliance, EDI capability, and agreement to a 3 percent administrative fee. Geographic scope extends across Minnesota, Oregon, and other participating MMCAP member states. Contract performance penalties range from $200 to $1,500 per violation for issues including late reporting, missed onboarding timelines, or improper class-of-trade denials.